BUS 303 MOD 1 SLP - Bristol-Myers Squibb Company TUI...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
Bristol-Myers Squibb Company TUI University (formerly Touro University International) Anthony J. Rayner BUS 303- Business Communication Module 1- The Role of the Financial Manager Session Long Project Dr. Glen Tenney (Core Professor) December 11, 2010, 2010 I will discuss what’s interesting about the company and whether or not the company will be successful in the future. Also, I will provide some financial highlights for the past year of Bristol-Myers Squibb Company and show what stock exchange the company is list on. Then go over their 12 month rate of return (% gain or loss) to investors who bought shares of this company a year ago and sold the shares yesterday. State the most recent price of shares on the company and dicuss some information about the top management team including the CEO and the CFO. I find Bristol-Myers Squibb Company very interesting because it is a global biopharmaceutical company that engages in discovering, developing, and delivering medicines that help patients prevail over serious diseases. The company focuses on areas of serious unmet medical need, such as affective (psychiatric) disorders, Alzheimer’s/dementia, cardiovascular (primarily atherosclerosis/thrombosis), diabetes, hepatitis, HIV/AIDS, obesity, oncology, rheumatoid arthritis and related diseases, and solid organ transplant. The company also has a pipeline with compounds in phase III clinical trials. Bristol-Myers Squibb Company sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies around the world. Bristol-Myers Squibb Company has various alliances and collaborations with many well-known pharmaceutical companies. Bristol-Myers Squibb Company is a pure biotechnology pharmaceutical after two years of transformation. As it moves away from selling health care products, the company is cutting $2.5 billion in costs by 2012. It’s also spinning off old businesses like Mead Johnson Nutritionals. Bristol-Myers Squibb Company earned $7.2 billion from the Mead IPO in 2009, which help them
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 09/18/2011 for the course BUS 303 taught by Professor Dr.glentenney during the Spring '11 term at Trident Technical College.

Page1 / 3

BUS 303 MOD 1 SLP - Bristol-Myers Squibb Company TUI...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online